Daily Biotech Movers — 2026-07-15: A Dilution-Print Day Where Small-Cap Biotech Routed While SPY Pushed to a New High

Wednesday, July 15, 2026 was a dilution-print day for small-cap biotech — a session where three clean fresh capital-raise catalysts (a strategic spin-off, a $10M registered direct offering, and a $200M public offering) each triggered a hard 15%–40% sell-the-news reaction, while three Class 4 / Class 5 continuation reads led the upside. The structural surprise was the broad-market backdrop: the S&P 500 ETF (SPY) closed +1.26% to a fresh high, while biotech-specific ETFs diverged sharply — XBI -4.14%, IBB -3.28%, XLV -2.47% — the steepest single-session biotech-ETF underperformance relative to SPY since the early-April tariff-shock window. Across the 587 public biotech and life-sciences companies in our coverage universe, 339 finished up while 225 finished down (a 1.5-to-1 advancer ratio), with a median move of +0.575%, a mean of +0.679%, a stdev of 4.618%, and 87 names crossing the anomaly threshold (|% change| >= 5% OR volume ratio >= 2x).

What makes today’s tape worth a synthesis post is the simultaneous occurrence of three structurally different distributions: the broadest 587-name tape was modestly green (median +0.58%), biotech-specific ETFs were sharply red (XBI -4.14%), and the top six movers each carried a discrete, name-specific narrative. Five of the six top names had hard primary-source catalysts; only one (BEAT) was a pure continuation. The 6-class taxonomy clears cleanly: Class 5 (sell-the-news / dilution-print) for all three losers, Class 4 (strategic-alternatives continuation) for IOVA, Class 4 / Class 5 hybrid (forward-looking earnings anticipation + analyst repricing) for RCEL, and Class 4 (multi-week corporate-presentation continuation) for BEAT. Today’s tape is a single-day cross-section of three things that matter for small-cap biotech investors heading into Q2 earnings: (a) issuance is back in force for clinical-stage biotech, (b) biotech ETFs can decouple from the long-tail of small/mid-cap biotech names when the largest constituents move, and (c) continuation trades can still outperform fresh reads when the fresh reads are capital-raises.

The Distribution

Across 587 public biotech/life-sciences companies on 2026-07-15:
  339 up   (avg +3.05%)
  225 down (avg -2.80%)
  Median:  +0.575%   Mean: +0.679%   StDev: 4.618%
  87 names moved |%|>= 5% (anomaly threshold)

Breadth was modestly positive on a 1.5-to-1 advancer-to-decliner ratio, with average upside (+3.05%) very slightly wider than average downside (-2.80% in absolute terms). The 4.62% standard deviation sits in the upper third of recent sessions — active but not panicked, with concrete name-level catalysts driving the dispersion rather than a coordinated risk-off. The 87 anomaly-flagged names include 13 names with double-digit moves, both upside and downside, with three concentrated -29% / -33% / -40% dilution prints on the loser side and three +17% to +21% continuation moves on the winner side.

The sector table told the granular story. Generic Drugs led the day at +4.17% across 5 names — a small bucket where individual single-stock moves can dominate the average. From there, the slope softened but stayed positive across the broad pharma / biologics base: Devices — Miscellaneous at +2.78% (n=25), Diagnostics at +2.52% (n=31), Devices — Surgical +1.39% (n=29), Drug Delivery / Formulation +1.36% (n=31), Biologics +0.73% (n=86), and the broad Small Molecule Pharma basket at +0.31% (n=147). The drag was concentrated in Psychedelics & Related at -1.98% (n=5), Devices — Imaging at -1.62% (n=8), and Devices — Drug Delivery at -1.94% (n=3). Reading the table in aggregate: small-bucket leadership did most of the work, the broad biologics / pharma / devices base was modestly positive, and the small thematic / niche buckets were modestly negative.

The clean structural read is the divergence between the 587-name aggregate tape (+0.58% median, 339 up) and the diversified biotech ETFs (XBI -4.14%, IBB -3.28%). Several large-cap biotech names that sit outside the 587-name coverage universe (mega-cap pharma and large-cap biotech benchmark components) appear to have led the XBI/IBB drawdown — the long tail of small/mid-cap biotechs we track was net positive on the day, in contrast to the ETF-level read. This is a meaningful nuance for anyone using XBI as a proxy for “the biotech tape” today: XBI closed at -4.14% but the median small-cap biotech in our universe closed at +0.58%. The two distributions are not the same.

The 6 Classes of Mover Signal

The 87 anomaly-flagged moves collapse into six signal classes. Today’s top six names break down as 3× Class 4 / Class 5 hybrid (continuation / forward-looking reads) on the winner side and 3× Class 5 (fresh dilution-print / strategic divestiture) on the loser side — a structural mix where the losers carry clean primary-source news and the winners are momentum / anticipation trades.

1. Halt-release or reverse-split-adjacent. No top-six name today fits this category. The closest adjacent signal in the broader anomaly set was CLRB (Cellectar Biosciences) at 5.64x volume on a -0.76% print — a stealth-distribution candidate rather than a halt-release. Today’s tape was distinguished from prior zero-clean-catalyst days by the absence of any reverse-split-adjacent print in the top six.

2. Single-stock clinical or regulatory event. No top-six name today was driven by a fresh same-day clinical readout, regulatory milestone, or comparable primary-discovery event. The lone fresh clinical signal adjacent to today’s tape is BEAT’s continued post-mortem of its late-June ALIGN-ACS pilot enrollment and the JACC: Advances publication — neither qualifies as a “today’s catalyst” by the timing definition used in prior daily syntheses.

3. Buyout or strategic capital. SNTI’s announcement of a Celadon-led strategic spin-off is the closest analog to a Class 3 transaction on the day, but the structure (an outbound carve-out of the most-valuable clinical asset to a controlling shareholder’s NewCo) is structurally an insider transaction rather than an inbound strategic-capital positive. QTTB’s $200M public offering of common stock and pre-funded warrants is also a Class 3-shaped transaction (external capital) but was received as a sell-the-news dilution-print event by the tape. Neither fits the canonical Class 3 (outbound strategic transaction at a premium with broad counterparty participation).

4. Sector rotation. The macro signal today is the day’s defining feature. SPY closed +1.26% to a fresh high but XBI -4.14% and IBB -3.28% underperformed by 5.40 and 4.54 percentage points respectively. This is the largest single-day XBI-vs-SPY divergence since the early-April tariff-shock window. The rotation reads as a defensive-flow-out of healthcare and biotech into broad-market cyclicals — a pattern not seen in this direction since May’s inflation-print window. None of the day’s three winners was a pure Class 4 sector rotation print, but IOVA’s continued leadership and RCEL’s pre-earnings positioning both benefit from the broader healthcare ETF bid that has built up over the past two weeks.

5. Sell-the-news / prior-cycle profit-taking / mechanical. All three of today’s top losers fit this category with clean fresh primary-source catalysts. SNTI (-39.71%) sold off on a today-announced strategic spin-off that hands the lead RMAT-designated asset (SENTI-202) to a controlling-shareholder NewCo in exchange for a contingent value right. CRDF (-32.11%) sold off on a today-announced $10M registered direct offering priced at $1.05 with warrants. QTTB (-14.95%) sold off on a today-announced $200M public offering of common stock and pre-funded warrants. All three are clean Class 5 sell-the-news / dilution-print events with hard, fresh, primary-source catalysts — the closest analog to today’s tape is the late-June issuing window where clinical-stage biotech stock repeatedly priced offerings into the close.

6. Stealth accumulation / distribution. CBIO (Crescent Biopharma) at +2.38% on 5.66x volume and CLRB (Cellectar Biosciences) at -0.76% on 5.64x volume are the day’s two stealth-mover candidates. CBIO has the cleaner accumulation profile: positive price, large volume, low absolute move suggests institutional accumulation rather than a price-driven catalyst. CLRB looks more like a stealth-distribution — large volume on a flat print. Neither name is in the top six on a price-change basis but both are flagged for watchlist follow-through.

Top 3 Winners — What Drove Them

Iovance Biotherapeutics (IOVA) — +20.61% on 2.95x volume

Iovance Biotherapeutics closed +20.61% at $4.74 on volume of 43.7M shares (close to 3x the 30-day average) — the day’s largest winner by both magnitude and volume confirmation. The move extends a multi-week rally rather than representing a fresh same-day catalyst. The most recent corporate communications on file include the company’s July 4 upward Q2 revenue guidance revision (to $86–$88M) and an updated FY2026 outlook, driven by accelerating Amtagvi (lifileucel) adoption — the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy in solid tumors (MarketInference IOVA coverage, 2026-07-04; Iovance corporate presentation update, July 2026). Today’s tape also absorbed positive market reaction to a competitor’s FDA rejection, which reinforced Iovance’s leading position in the TIL therapy space, plus disclosed insider buying by the Chief Commercial Officer (30,000 shares filed in mid-July) (Iovance insider Form 4 filing, July 2026). With 5-day momentum at +10.75%, today’s move is the third leg of a multi-session rebound that began in late June. Signal class: Class 4 — multi-week guidance-rally continuation. Prior-cycle catalyst — flagged.

HeartBeam (BEAT) — +17.71% on 2.22x volume

HeartBeam closed +17.71% at $0.66 on volume of 2.32M shares (2.22x the 30-day average). The move sits at the intersection of three positive developments sequenced over the past two weeks. On June 30, the company announced completion of enrollment in its ALIGN-ACS pilot study for heart attack detection at 120 patients — ahead of schedule and signaling strong execution on its key strategic priority (HeartBeam ALIGN-ACS enrollment completion, 2026-06-30). In parallel, a peer-reviewed study in JACC: Advances demonstrated that HeartBeam’s portable ECG device can help identify heart attack risk, providing clinical validation of the technology (HeartBeam JACC: Advances study, 2026). On July 1, the company advanced its ECG-data use announcement for non-hospital settings (HeartBeam ECG data expansion, 2026-07-01). Today’s move reflects continued momentum from these overlapping catalysts rather than a single today-specific event. With 5-day momentum at +5.53%, the position has been building on this stack since late June. Signal class: Class 4 / Class 5 hybrid — multi-week clinical-and-corporate momentum. Prior-cycle catalyst — flagged.

AVITA Medical (RCEL) — +17.66% on 1.21x volume

AVITA Medical closed +17.66% at $4.73 on volume of 412,568 shares (1.21x the 30-day average — a comparatively modest volume confirmation for a +17.66% move). Today’s move was driven by a convergence of analyst activity and forward-looking corporate positioning. On July 14, AVITA announced it will report Q2 2026 financial results on August 6, signaling ongoing business momentum in the RECELL System commercial trajectory (AVITA Q2 2026 earnings announcement, 2026-07-14). On the same day, analyst coverage raised AVITA’s fair-value estimate from approximately $6.98 to $9.00 per share, citing RECELL product momentum (AVITA analyst fair-value estimate raise, July 2026; Zacks Rank #2 upgrade, July 2026). Insider activity also confirmed institutional confidence: a company director purchased 10,000 shares on the open market, with all five insider trades in the past six months being purchases with zero sales (RCEL insider Form 4 filing, July 2026). With 5-day momentum at +1.72%, today’s move is the third leg of a multi-session advance leading into the August 6 print. Signal class: Class 4 — pre-earnings positioning + analyst repricing.

Top 3 Losers — What Drove Them

Senti Biosciences (SNTI) — -39.71% on 10.62x volume

Senti Biosciences closed -39.71% at $0.58 on volume of 2.69M shares (10.62x the 30-day average — by far the most concentrated volume in the day’s anomaly table). Today’s move is a clean Class 5 sell-the-news event on a today-announced strategic spin-off transaction. The company announced the formation of a new private company (“NewCo”) controlled by Celadon Partners (Senti’s largest investor) that will acquire the Gene-Circuit-enabled pipeline — including SENTI-202, the company’s lead RMAT-designated CAR-NK cell therapy for relapsed/refractory AML — in exchange for a contingent value right (CVR) worth up to $60M in milestone payments over seven years (Senti Biosciences strategic spin-off announcement, 2026-07-15). Post-transaction, Senti plans to pivot to early-stage programs on its Regulator Dial platform (controllable gene therapy for Rett Syndrome, armored TILs for solid tumors) and will need additional financing — implying further dilution risk for existing shareholders. The CVR structure valued SENTI-202 at significantly less than the public market had been pricing the asset, which is the primary mechanism of the sell-off. With 5-day momentum of -43.91%, today’s move accelerates a slide that began shortly after the prior-month’s financing announcements. Signal class: Class 5 — strategic-spin-off / asset-migration sell-the-news event with insider-counterparty structure.

Cardiff Oncology (CRDF) — -32.11% on 7.34x volume

Cardiff Oncology closed -32.11% at $0.89 on volume of 12.71M shares (7.34x the 30-day average). Today’s move is a clean Class 5 sell-the-news event on a today-announced $10M registered direct offering. The company priced 8,571,429 common shares at $1.05 per share with accompanying warrants to purchase up to an equivalent number of shares at an exercise price of $1.31, totaling over 9.3M new shares including a separate insider tranche of 731,707 shares at $1.435 (Cardiff Oncology press release / StockTitan coverage, 2026-07-15; Yahoo Finance Cardiff dilution coverage, 2026-07-15). The dilutive raise — below-market pricing, massive warrant overhang, and the stock already trading more than 70% below its 52-week high — triggered a sharp selloff as the market interpreted the structure as a liquidity-stress signal (Cardiff Oncology warrant-and-insider tranche filing, 2026-07-15). With 5-day momentum of -28.86%, this is the continuation of a multi-day slide that began pre-announcement. Signal class: Class 5 — registered-direct-offering dilution-print sell-the-news.

Q32 Bio (QTTB) — -14.95% on 3.69x volume

Q32 Bio closed -14.95% at $15.70 on volume of 7.06M shares (3.69x the 30-day average). Today’s move is a clean Class 5 sell-the-news event on a today-announced $200M public offering of common stock and pre-funded warrants — the company’s largest capital raise to date. The offering was priced at $18.25 per share with an overallotment option that could lift total proceeds to approximately $216M, intended to fund Q32 Bio’s clinical development pipeline including the SIGNAL-AA trial program (Q32 Bio press release, 2026-07-15; GuruFocus Q32 Bio dilution coverage, 2026-07-15). Net proceeds of approximately $187.6M spooked investors despite Wall Street analysts maintaining an 80% upside consensus target — the sheer scale of dilution overwhelmed the bullish consensus (Q32 Bio analyst consensus, 2026-07-15). With 5-day momentum of +11.51%, the stock had been building into the offering and today’s print is the standard session-after-pricing reset. Signal class: Class 5 — public-offering dilution-print sell-the-news.

The Cross-Cutting Pattern

The day’s pattern was a dilution-print day for clinical-stage biotech, with all three top losers driven by today-announced capital-raise or spin-off transactions and the broader biotech ETF complex diverging sharply from the broad market and from the long-tail of small/mid-cap names. SPY closed +1.26% to a fresh high — the strongest single-day broad-market print in nearly a month — but XBI -4.14% and IBB -3.28% underperformed by 5.40 and 4.54 percentage points respectively. The XBI-vs-SPY gap of 5.40 percentage points is the steepest single-session biotech-ETF underperformance since the early-April tariff-shock window; the implication is that defensive flows out of healthcare and biotech into broad-market cyclicals dominated today’s sector rotation despite the strong SPY close.

The dilution-print concentration on the loser side is the most important structural observation. SNTI, CRDF, and QTTB all closed -14.95% to -39.71% on today-announced primary-source catalysts (a strategic spin-off to a controlling-shareholder NewCo; a $10M registered direct offering; a $200M public offering). All three are clean Class 5 sell-the-news events with hard, primary-source catalysts dated July 15 — these are not continuation moves or stealth distributions, they are fresh same-day revelations of capital structure. Three clean capital-raise print losses in one session is the densest single-day issuance-driven drawdown the small-cap biotech tape has seen since the late-May offering window. The 10.62x volume confirmation on SNTI, 7.34x on CRDF, and 3.69x on QTTB all reflect institutional participation in the post-news repricing, not retail-driven panic.

The winner side has a different shape. IOVA, BEAT, and RCEL each closed +17.66% to +20.61% on continuation / forward-looking reads — multi-week momentum trades that benefited from the past two weeks of stacked positive catalysts (Q2 guidance raises, clinical publication, analyst upgrades, Q2 earnings schedule). None was a fresh today-specific discovery catalyst. Today’s move extended running positions in preparation for the August catalyst calendar. The 5-day momentum stack is +10.75% / +5.53% / +1.72% — winners had established multi-session uptrends; today’s tape amplified those trends rather than creating new direction.

The relative sector leaders reinforce the read. Generic Drugs led the day at +4.17% across 5 names — a small bucket where individual single-stock moves can dominate the average. The second and third slots went to Devices — Miscellaneous at +2.78% across 25 names and Diagnostics at +2.52% across 31 names. From there, every broad therapeutic bucket was modestly positive: Biologics +0.73% (n=86), Small Molecule Pharma +0.31% (n=147), Drug Delivery / Formulation +1.36% (n=31). The day’s worst broad bucket was Devices — Drug Delivery at -1.94% across just 3 names (small-bucket noise), and the Psychedelics & Related bucket at -1.98% across 5 (also small-bucket noise). The clean read is that the broad pharma-bucket base was modestly positive at the long-tail level; the diversified biotech-ETF level (XBI/IBB) was held back by larger-cap constituents not in our coverage universe.

One observation that complicates the read: today’s 87 anomalies are fewer than yesterday’s 103 anomalies but the stdev is wider (4.62% vs 4.36%). So even though the day had less anomaly count, the day’s anomalies were more dispersed — the three dilution-print losers anchored the right tail while the three continuation winners anchored the left tail, with a wide mid-distribution of less-extreme moves. When a tape is both lower-anomaly-count and higher-stdev, it usually means institutional money is rotating at the largest constituents while the small/mid-cap long-tail is consolidating. That matches the XBI-vs-SPY 5.4-point gap: the rotation is happening at the ETF level (largely held by larger caps) while the long tail is grinding modestly higher on issuance-driven dispersion.

The single most important signal from today’s tape is the disconnect between capital-raise news and broad-market backdrop. SPY pushed to a fresh high on the day — the strongest single-day print in a month — but biotech saw three concurrent fresh dilution prints and a sharp ETF drawdown. The cleanest read is that clinical-stage biotech issuers are returning to the offering window after the post-ASCO lull, and the broad-market backdrop is not absorbing the issuance well. When issuance resumes at scale into a defensive-sector rotation, the dilution-print discounts compound — and today’s three-name concentration is the cleanest example yet of how that compound works in real time.

The 5 Data Points That Matter

1. % change vs. sector move. IOVA at +20.61% beat the 587-name median (+0.58%) by 20.03 percentage points; BEAT at +17.71% by 17.13 points; RCEL at +17.66% by 17.08 points — but on continuation reads rather than fresh discovery. SNTI at -39.71% underperformed by 40.29 points; CRDF at -32.11% by 32.69 points; QTTB at -14.95% by 15.53 points — and these three are fresh dilution prints with hard primary-source catalysts. Versus XBI -4.14%: IOVA +20.61% beat XBI by 24.75 points; SNTI -39.71% underperformed by 35.57 points. The signal clears: winners are continuation, losers are dilution, and the day’s %-vs-sector gaps cleanly classify the moves.

2. Volume ratio. SNTI at 10.62x had the cleanest volume confirmation of any mover today — institutional participation in the post-spin-off repricing was real. CRDF at 7.34x had the second-cleanest — the $10M direct offering hit the tape with full institutional rebalancing. QTTB at 3.69x had solid confirmation for a $200M public offering. IOVA at 2.95x had the day’s most concentrated buyer-side volume confirmation among the winners. BEAT at 2.22x had solid confirmation on a continuation move. RCEL at 1.21x had the weakest volume confirmation of the top six — the +17.66% move was real but not institutionally participation-heavy.

3. 5d momentum. IOVA at +10.75% was a multi-day rebound paying off; BEAT at +5.53% was a multi-week follow-through off the late-June clinical-and-corporate stack; RCEL at +1.72% was an early-stage pre-earnings build. SNTI at -43.91% and CRDF at -28.86% were multi-session continuation drops into today’s dilution-print; QTTB at +11.51% was a multi-session build that ended in today’s offering reset. The momentum profile tells us: winners had established 1-3 week uptrends; the dilution-print losers were either slide-into-news (SNTI, CRDF) or build-into-news (QTTB). Today’s tape processed capital structure news rather than creating new direction.

4. 52-week range. IOVA at $4.74 sits in the upper third of its 52-week range after the multi-week rally; the catalyst-stacked $4.50s to $5.00s is a fresh consolidation zone. BEAT at $0.66 sits well below its 52-week high after the multi-week slide — even today’s +17.71% print leaves the stock below midrange. RCEL at $4.73 sits well below the consensus analyst target of $9.00 — substantial upside remains priced in. SNTI at $0.58 sits near multi-year lows after the spin-off transaction announced today. CRDF at $0.89 sits more than 70% below its 52-week high after the dilution print. QTTB at $15.70 has now slipped below the offering price of $18.25 from today’s transaction — typical session-after-pricing reset.

5. Cash / dilution context. QTTB has the cleanest cash story on the day — the $200M public offering extends runway into the back half of 2029 — yet the tape reacted negatively because the dilution wiped out the near-term price action. SNTI’s spin-off transaction offloads the lead RMAT-designated asset to a controlling-shareholder NewCo in exchange for a CVR worth up to $60M — the company will need to raise additional capital to fund its pivot to early-stage programs, signaling further dilution risk. CRDF’s $10M direct offering at below-market pricing plus massive warrant overhang signals acute liquidity stress — the dilution was a fraction of the company’s stated cash need. IOVA has the inverse story: the company’s July 4 guidance raise and CCO insider buying both signal confidence in commercial Amtagvi trajectory. BEAT’s June 30 enrollment completion and JACC: Advances publication strengthen the strategic narrative ahead of any fresh capital-raise window. RCEL’s August 6 Q2 print is the next binary event.

What This Synthesis Will and Won’t Tell You

It will tell you what moved on July 15, why three small-cap biotech names dropped 15%–40% on clean fresh dilution-print catalysts, why biotech ETFs diverged sharply from a broadly positive broad-market tape (XBI -4.14% vs SPY +1.26%), and why a +1.26% SPY day and a modestly positive 587-name small/mid-cap aggregate can coexist with three hard dilution-print losers. The single cleanest read is the issuance concentration: three clean primary-source capital-raise or asset-migration prints in one session is the densest single-day issuance drawdown the small-cap biotech tape has seen since the late-May offering window, and it’s worth tracking whether tomorrow’s session sees a fourth or fifth comparable print.

It will not tell you whether IOVA’s multi-week rally will sustain into the next earnings print, whether BEAT’s clinical-and-corporate momentum will translate into a fresh Class 3 strategic partnership, whether AVITA’s August 6 print will beat the new $9.00 analyst fair-value estimate, whether Senti’s CVR structure will eventually be renegotiated or restructured, whether Cardiff Oncology will need to tap the capital markets again within the next two quarters to extend runway, whether Q32 Bio’s $200M raise will fully fund the SIGNAL-AA program through topline readout, or whether the broad-market-vs-biotech-ETF divergence will resolve in the next 30 days. These are multi-week and multi-month questions. Wednesday’s tape answers only the first question: where did capital go today, and which signals were clean fresh dilution prints versus continuation / forward-looking reads?

A note on issuance-day patterns. The 2026-07-15 daily synthesis post is the first one in this site to feature three concurrent fresh dilution-print prints at the top of the loser list. The prior closest analog was 2026-07-06 (zero-clean-catalyst day, but no fresh dilution prints). The honest read for the reader is that clinical-stage biotech issuance has re-engaged after the post-ASCO / pre-Q2-earnings lull, and the broad-market backdrop is not currently absorbing the issuance well — each print is producing 30%+ dilution discounts on the day. When issuance resumes at scale into a defensive-sector rotation, today’s tape is the cleanest reference example of how the discount compounds. The Aug 2 Q1 FY2027 print from several of these issuers will be the next catalytic event to test whether the issuance discounts unwind or persist.

This is editorial analysis, not investment advice. Single-day % returns reflect closing prices on 2026-07-15 and will move with market conditions and clinical readouts. Several top performers carry volatility and reversal flags — review the watch-flag notes for IOVA, BEAT, RCEL, SNTI, CRDF, and QTTB before drawing conclusions about momentum durability. The 87 anomaly-flagged names include stealth-mover candidates CBIO and CLRB which are flagged for follow-through.

About the Underlying Dataset

The full report with all 587 companies, the 87 anomaly-flagged moves, and the why-investigation source links is in the published analysis archive at openbionews.com. The dataset covers every US-listed public biotech and life-sciences company indexed from public company career pages, financial disclosures, and regulatory filings — refreshed daily from primary public sources. Foreign ADRs and OTC pink-sheet tickers that cannot be resolved against a US exchange feed are excluded from the distribution statistics but retained in the universe count. The Profiled Companies right-rail sidebar for this post currently shows one matched company profile (Q32 Bio); the other five of today’s top movers (Iovance Biotherapeutics, HeartBeam, AVITA Medical, Senti Biosciences, Cardiff Oncology) do not yet have profiles in the company-collection directory, an acknowledged coverage gap that does not affect the report’s substance.

Sources: Iovance Biotherapeutics corporate presentation update, July 2026; Iovance Biotherapeutics insider Form 4 filing, July 2026; Iovance coverage and Q2 guidance context, July 2026; HeartBeam ALIGN-ACS enrollment completion, 2026-06-30; HeartBeam JACC: Advances clinical study, 2026; HeartBeam ECG data expansion, 2026-07-01; AVITA Medical Q2 2026 earnings announcement, 2026-07-14; AVITA Medical analyst fair-value estimate raise, July 2026; AVITA Medical Zacks Rank #2 upgrade, July 2026; RCEL insider Form 4 filing, July 2026; Senti Biosciences strategic spin-off announcement, 2026-07-15; Cardiff Oncology $10M registered direct offering press release, 2026-07-15; Cardiff Oncology dilution coverage, 2026-07-15; Cardiff Oncology warrant-and-insider tranche filing, 2026-07-15; Q32 Bio $200M public offering press release, 2026-07-15; Q32 Bio dilution coverage, 2026-07-15; Q32 Bio analyst consensus, 2026-07-15; daily news-services cycle scan and public-company disclosure refresh for 2026-07-15 closing prices and broad-market ETF context.